Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.
Emilio PortaccioLuisa PastòLorenzo RazzoliniLucia MoiolaVittorio MartinelliPietro AnnovazziAngelo GhezziMauro ZaffaroniRoberta LanzilloVincenzo Brescia MorraFrancesca RinaldiPaolo GalloClaudio GasperiniDamiano PaolicelliMarta SimoneCarlo PozzilliLaura De GiglioPaola CavallaEleonora CoccoMaria Giovanna MarrosuFrancesco PattiClaudio SolaroGiancarlo ComiMassimo FilippiMaria TrojanoMaria Pia AmatoPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)
Our data confirm that TA reduces the risk of disease activity; we did not observe an increase in major development abnormalities in the child.
Keyphrases
- multiple sclerosis
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- pregnancy outcomes
- juvenile idiopathic arthritis
- white matter
- mental health
- preterm birth
- electronic health record
- big data
- pregnant women
- birth weight
- machine learning
- body mass index
- weight gain
- artificial intelligence